Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SDCBP | O00560 | 1/20 | 0.44 |
| ▸ | SDC2 | P34741 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11605717 | 0.82 | TSHR (0.42) | MEN1KMT2ALMNASDCBPSDC2 | |
| SCHEMBL11574943 | 0.82 | HPGD (0.57) | MEN1KMT2APPARAKDM4ELMNA | |
| SCHEMBL5110593 | 0.82 | GAA (0.53) | MEN1KMT2AHTTKDM4ELMNA | |
| SCHEMBL10455022 | 0.82 | KDM4E (0.47) | HTTKDM4ELMNAHSD17B10ALDH1A1 | |
| SCHEMBL10455020 | 0.82 | KDM4E (0.47) | HTTKDM4ELMNAHSD17B10ALDH1A1 | |
| SCHEMBL1931354 | 0.81 | KDM4E (0.51) | KDM4ELMNAHSD17B10ALDH1A1EPHX1 | |
| SCHEMBL28187258 | 0.81 | MEN1 (0.49) | MEN1KMT2APPARAHTTKDM4E | |
| SCHEMBL7398296 | 0.80 | CYP2C9 (0.66) | PPARAHTTKDM4ELMNASDCBP | |
| SCHEMBL875038 | 0.80 | KDM4E (0.46) | HTTKDM4ELMNAHSD17B10ALDH1A1 | |
| SCHEMBL16334438 | 0.79 | ALDH1A1 (0.46) | MEN1KMT2AKDM4EALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2221296-B1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-8211907-B2 | Fused indane compound | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-8211907-B2 | Fused indane compound | ASTELLAS PHARMA INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20100267695-A1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100267695-A1 | FUSED INDANE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-0970046-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-12 | — | — | EP | disclosed |
| EP-0874808-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998038163-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5665777-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
| WO-1997018188-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1997-05-22 | — | — | WO | disclosed |
| US-4156011-A | TREATMENT OF CARDIOVASCULAR DISORDERS | SOCIETE ANONYME DITE: LABORATOIRE L. LAFON (FR) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267695-A1 | FUSED INDANE COMPOUND | GRIN2A, GRIN2C, GRIN1 | MEN1 1227/4885KMT2A 1160/4885PPARA 3384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.